Pieris Pharmaceuticals Stock News

PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, is being developed as a local treatment for idiopathic pulmonary fibrosis Grant t

BOSTON, MA / ACCESSWIRE / June 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® techno

Are these biotech penny stocks to watch on your list for July 2021? The post Best Biotech Penny Stocks to Buy Next Month?

Investing in penny stocks in June? Check these 3 out today The post Hot Penny Stocks to Buy?

Best Robinhood penny stocks for Summer 2021? Check these 4 out The post 4 Robinhood Penny Stocks to Watch in Summer 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock

Pieris Pharmaceuticals (PIRS) stock is rising higher on Wednesday after announcing a collaboration agreement with Genentech. The post PIRS Stock: The Big News That Has Pieris Pharma Shares Rising Toda

Investors need to pay close attention to Pieris (PIRS) stock based on the movements in the options market lately.

Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?

The stock price of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) increased by 103.24% yesterday. This is why it happened.

Shares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology collaboratio

Current & former penny stocks trading higher after surge of interest in biotech industry. The post Trading Penny Stocks?

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares are trading higher by 57% at $2.91 after the company announced a respiratory and ophthalmology collaboration with Genentech. Pieris Pharmaceuticals is a

The stock price of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) increased by over 30% pre-market. This is why it happened.

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q1 2021 Results - Earnings Call Transcript

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 58.82% and 141.77%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock